Diligence. Following receipt of Regulatory Approval for a Licensed Product in a Major Market, Acadia (and its Affiliates and Sublicensees, as applicable) shall use Commercially Reasonable Efforts to ​. Acadia shall conduct all such Commercialization in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws.

Diligence. Licensee shall use Commercially Reasonable Efforts to commercialize the Licensed Products throughout the Territory so as to maximize Net Sales throughout the Territory.

Diligence. With respect to each Development Program for [[Unknown Identifier]] and ​ Targets, Acadia shall use Commercially Reasonable Efforts to ​. On a Development Program-by-Development Program basis, Acadia shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or Sublicensees) such Development Program in accordance with the Development Plan, including the timeframes set forth therein. Acadia shall conduct each Development Program in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws.

Diligence. After the Effective Date, as between the Parties, and for clarity, excluding the Know-How Transfer to be performed by [[AstraZeneca:Organization]] under Section 3.1, Licensee shall be solely responsible for all aspects of the development of the Licensed Compound and Licensed Products in the Field in the Territory. Licensee shall use Commercially Reasonable Efforts to develop, and obtain and maintain Regulatory Approvals for, Licensed Products for use in the Field throughout the Territory. Licensee shall perform or cause to be performed its development activities hereunder in good scientific manner and in compliance with all Applicable Law by allocating sufficient time, effort, equipment, and skilled personnel to complete such development activities.

Diligence. Licensor shall undertake to complete the Development Plan with similar resources and urgency to its own high priority projects (such efforts, “Diligent Efforts”).

Diligence. Licensee will use Commercially Reasonable Efforts to Develop (including filing NDAs and seeking Regulatory Approval) at least one Product in the Field in ​. Following receipt of Regulatory Approval in any such countries, Licensee will use Commercially Reasonable Efforts to Commercialize at least one Product in the Field in such countries.

Diligence. On a Research Program-by-Research Program basis, during the applicable Research Term, Stoke shall conduct the Research Program in accordance with this Agreement. Without limiting the foregoing, on a Research Plan-by-Research Plan basis, Stoke shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or by permitted subcontracting) its obligations under such Research Plan in accordance with the timeframes set forth therein. Stoke shall conduct each Research Program in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws. For clarity, for a given Research Program, Stoke shall not be required to perform any work which is not included in the applicable then-current Research Plan and corresponding Research Budget approved in accordance with this Agreement.

Diligence. Each Party shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or by permitted subcontracting) the activities assigned to it under the then-current [[Unknown Identifier]] Co-Development Plan in accordance with the timeframes set forth therein. Each Party shall conduct such activities in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws. All Development activities (other than those activities set forth in the [[Unknown Identifier]] Research Plan), including Clinical Trials, for [[Unknown Identifier]] Co-Co Products in the Territory shall be conducted solely as set forth in the relevant [[Unknown Identifier]] Co-Development Plan, and the Parties shall not perform any Development activities in the Territory for any [[Unknown Identifier]] Co-Co Product other than those set forth in the applicable [[Unknown Identifier]] Co-Development Plan. In the event a Party wishes to conduct a Development activity with respect to a [[Unknown Identifier]] Co-Co Product that is not included in the current applicable [[Unknown Identifier]] Co-Development Plan or [[Unknown Identifier]] Research Plan, e.g., with respect to a new formulation or indication, then such Party may propose such new Development activity to the JDC for consideration.

Diligence. Each Party will use Commercially Reasonable Efforts to perform the obligations assigned to it under the Joint Commercialization Plan. Upon receipt of the Regulatory Approval for a Licensed Product in the Field in a given country in the Territory, GSK (directly, or through its Affiliates, its or their Sublicensees or subcontractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such country in the Territory.

Diligence. Each Party shall use Commercially Reasonable Efforts to conduct the Research Collaboration by performing the activities allocated to such Party pursuant to this Agreement and the Development Plan (including any activities relating to New Research Programs that the Parties mutually agree to include within the scope of the Research Collaboration).